

# Anil Kapoor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2003017/publications.pdf>

Version: 2024-02-01

381  
papers

13,948  
citations

70961

41  
h-index

24915

109  
g-index

394  
all docs

394  
docs citations

394  
times ranked

16073  
citing authors

#	ARTICLE	IF	CITATIONS
1	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.	13.9	3,490
2	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	13.9	3,337
3	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
4	Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. <i>Journal of Urology</i> , 2019, 202, 282-289.	0.2	248
5	Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shock wave lithotripsy for urinary calculi. <i>BJU International</i> , 2005, 95, 1285-1288.	1.3	169
6	Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. <i>BJU International</i> , 2012, 110, 510-516.	1.3	168
7	Apoptotic Release of Histones from Nucleosomes. <i>Journal of Biological Chemistry</i> , 2002, 277, 12001-12008.	1.6	109
8	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 913.	3.4	107
9	Regulation of the Tumor Suppressor PTEN through Exosomes: A Diagnostic Potential for Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e70047.	1.1	106
10	Guidelines for the management of the incidentally discovered adrenal mass. <i>Canadian Urological Association Journal</i> , 2011, 5, 241-247.	0.3	102
11	Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 683-694.	1.9	97
12	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015, 9, 90.	0.3	82
13	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. <i>Oncotarget</i> , 2015, 6, 1900-1919.	0.8	80
14	Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. , 1997, 32, 129-139.		78
15	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. <i>Blood</i> , 2015, 125, 195-198.	0.6	78
16	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
17	Laparoscopic versus open partial nephrectomy. <i>Urology</i> , 2004, 64, 458-461.	0.5	75
18	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019, 11, 434.	1.7	74

#	ARTICLE	IF	CITATIONS
19	Nuclear Factor-E2-related Factor-1 Mediates Ascorbic Acid Induction of Osterix Expression via Interaction with Antioxidant-Responsive Element in Bone Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 22052-22061.	1.6	73
20	Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney. <i>European Urology</i> , 2008, 54, 866-874.	0.9	73
21	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. <i>PLoS ONE</i> , 2017, 12, e0173358.	1.1	71
22	Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. <i>Cancer</i> , 2009, 115, 3618-3630.	2.0	70
23	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016, 94, 154-160.	0.5	60
24	Contributions of DNA Damage to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1666.	1.8	60
25	Î±-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. <i>Nature Communications</i> , 2011, 2, 307.	5.8	56
26	Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. <i>BJU International</i> , 2017, 119, 543-549.	1.3	56
27	Spontaneous Fractures in the Mouse Mutant sfx Are Caused by Deletion of the Gulonolactone Oxidase Gene, Causing Vitamin C Deficiency. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1597-1610.	3.1	55
28	The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1028.	1.7	54
29	Bmi1 promotes prostate tumorigenesis via inhibiting p16INK4A and p14ARF expression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 642-648.	1.8	53
30	The Contemporary Role of Lymph Node Dissection During Nephroureterectomy in the Management of Upper Urinary Tract Urothelial Carcinoma: The Canadian Experience. <i>Urology</i> , 2012, 79, 840-845.	0.5	53
31	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018, 124, 3677-3683.	2.0	53
32	Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 975-987.	1.1	52
33	Intact Specimen Extraction in Laparoscopic Nephrectomy Procedures: Pfannenstiel Versus Expanded Port Site Incisions. <i>Urology</i> , 2007, 69, 241-244.	0.5	51
34	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.3	51
35	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. <i>BJU International</i> , 2013, 112, 791-797.	1.3	49
36	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e17-31.e24.	0.8	49

#	ARTICLE	IF	CITATIONS
37	Results of the ADAPT Phase 3 Study of Rocabudencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2327-2336.	3.2	49
38	IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 875-884.	1.8	48
39	Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. <i>European Journal of Cancer</i> , 2017, 70, 62-74.	1.3	48
40	Canadian guidelines for the management of the small renal mass (SRM). <i>Canadian Urological Association Journal</i> , 2015, 9, 160.	0.3	45
41	PTEN inhibits BMI1 function independently of its phosphatase activity. <i>Molecular Cancer</i> , 2009, 8, 98.	7.9	44
42	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 839-845.	0.8	44
43	Using the Delphi Technique to Improve Clinical Outcomes Through the Development of Quality Indicators in Renal Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2013, 9, e262-e267.	2.5	43
44	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.	0.4	42
45	Malignancy in Kidney Transplant Recipients. <i>Drugs</i> , 2008, 68, 11-19.	4.9	41
46	High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. <i>Histopathology</i> , 2019, 75, 440-442.	1.6	41
47	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019, 5, 488-496.	1.6	41
48	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. <i>Cancer Research</i> , 2016, 76, 1603-1614.	0.4	40
49	ATM activity contributes to the tumor-suppressing functions of p14ARF. <i>Oncogene</i> , 2004, 23, 7355-7365.	2.6	39
50	Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores. <i>Journal of Biological Chemistry</i> , 2010, 285, 28912-28923.	1.6	39
51	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017, 35, 355-365.	1.2	39
52	An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies. <i>Acta Cirurgica Brasileira</i> , 2013, 28, 870-876.	0.3	37
53	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e1-486.e7.	0.8	37
54	Comparison of Laparoscopic Radical Renal Surgery in Morbidly Obese and Non-obese Patients. <i>Journal of Endourology</i> , 2004, 18, 657-660.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Robot-assisted laparoscopic renal artery aneurysm reconstruction. <i>Journal of Vascular Surgery</i> , 2006, 44, 651-653.	0.6	36
56	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1161-1165.	0.8	36
57	Laparoscopic Management of Advanced Renal Cell Carcinoma With Renal Vein and Inferior Vena Cava Thrombus. <i>Urology</i> , 2014, 83, 812-817.	0.5	36
58	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017, 49, 2143-2149.	0.6	36
59	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	1.1	35
60	Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. <i>Urology</i> , 2006, 68, 514-517.	0.5	34
61	ATM activation is accompanied with earlier stages of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 1090-1097.	1.9	33
62	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017, 11, 182.	0.3	33
63	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014, 8, 845.	0.3	32
64	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
65	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 16-24.	0.2	31
66	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.	0.3	30
67	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT2 non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	1.3	30
68	Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2021, 45, 75-90.	0.5	30
69	Transfer of Laparoscopic Radical Prostatectomy Skills From Bench Model to Animal Model: A Prospective, Single-Blind, Randomized, Controlled Study. <i>Journal of Urology</i> , 2012, 187, 1861-1866.	0.2	29
70	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	1.3	29
71	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. <i>The Cochrane Library</i> , 2017, 2017, CD010098.	1.5	29
72	Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. <i>European Journal of Cancer</i> , 2013, 49, 3537-3546.	1.3	28

#	ARTICLE	IF	CITATIONS
73	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Canadian Urological Association Journal, 2014, 8, 398.	0.3	28
74	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1â€”2 NO MO renal cell carcinoma. World Journal of Urology, 2017, 35, 1899-1905.	1.2	28
75	Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget, 2016, 7, 83115-83133.	0.8	27
76	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 441-448.	0.8	26
77	Upregulation of FAM84B during prostate cancer progression. Oncotarget, 2017, 8, 19218-19235.	0.8	26
78	Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 1134-1142.	1.8	25
79	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e17-486.e23.	0.8	25
80	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer, 2019, 108, 69-77.	1.3	25
81	Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. Current Oncology, 2011, 18, 5-10.	0.9	25
82	Contemporary agents in the management of metastatic castration-resistant prostate cancer. Canadian Urological Association Journal, 2016, 10, 414.	0.3	24
83	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€”Targeted <sup>18</sup> F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	2.8	24
84	Benign prostatic hyperplasia (BPH) management in the primary care setting. Canadian Journal of Urology, 2012, 19 Suppl 1, 10-7.	0.0	24
85	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). Urology, 2016, 89, 19-26.	0.5	23
86	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 768-780.	5.1	23
87	Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Canadian Urological Association Journal, 2013, 3, 143.	0.3	22
88	Update on medical expulsive therapy for distal ureteral stones: Beyond alpha-blockers. Canadian Urological Association Journal, 2014, 8, 442.	0.3	22
89	Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression. Neoplasia, 2017, 19, 857-867.	2.3	22
90	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.3	21

#	ARTICLE	IF	CITATIONS
91	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 721-726.	0.8	21
92	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019, 5, 467-473.	1.6	21
93	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	0.8	21
94	Adenovirus-Mediated Gene Transfer of TGF- $\beta$ 1 to the Renal Glomeruli Leads to Proteinuria. <i>American Journal of Pathology</i> , 2012, 180, 940-951.	1.9	20
95	Anastomosing Hemangioma of the Kidney: Radiologic and Pathologic Distinctions of a Kidney Cancer Mimic. <i>Current Oncology</i> , 2018, 25, 220-223.	0.9	20
96	Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011. <i>Canadian Urological Association Journal</i> , 2012, 6, 16-22.	0.3	19
97	Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease. <i>Canadian Urological Association Journal</i> , 2013, 7, 108-13.	0.3	19
98	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. , 2016, 4, CD010098.		19
99	Use of SNAPPS model for pediatric outpatient education. <i>Indian Pediatrics</i> , 2017, 54, 288-290.	0.2	19
100	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	0.8	19
101	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 688-696.	0.8	19
102	Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2016, 20, 82-8.	0.3	19
103	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.3	18
104	SDH-deficient renal cell carcinoma – clinical, pathologic and genetic correlates: a case report. <i>BMC Urology</i> , 2018, 18, 109.	0.6	18
105	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 799.e1-799.e10.	0.8	18
106	Laparoscopic Nephrectomy with Intact Specimen Extraction for Polycystic Kidney Disease. <i>Journal of Endourology</i> , 2008, 22, 675-680.	1.1	17
107	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , 2017, 292, 21180-21192.	1.6	17
108	FAM84B promotes prostate tumorigenesis through a network alteration. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984637.	1.4	17



#	ARTICLE	IF	CITATIONS
109	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal, 2019, 14, 17-23.	0.3	17
110	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. Journal of Urology, 2020, 204, 671-676.	0.2	17
111	Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study. Urology, 2015, 86, 1174-1178.	0.5	16
112	Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. Scandinavian Journal of Urology, 2016, 50, 234-238.	0.6	16
113	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 176-183.	0.9	16
114	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World Journal of Urology, 2018, 36, 51-57.	1.2	16
115	Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. Current Oncology, 2018, 25, 576-584.	0.9	16
116	Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development. Translational Oncology, 2018, 11, 1012-1022.	1.7	16
117	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association Journal, 2018, 12, 173-80.	0.3	16
118	Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2021, 39, 4502-4502.	0.8	16
119	Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma. Oncotarget, 2014, 5, 7406-7419.	0.8	16
120	Effect of <sup>18</sup> F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	3.6	16
121	Comparison of laparoscopic and open nephrectomy for adult polycystic kidney disease: operative challenges and technique. Canadian Journal of Urology, 2006, 13, 3340-5.	0.0	16
122	Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Canadian Urological Association Journal, 2007, 1, 27-38.	0.3	15
123	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. Canadian Urological Association Journal, 2013, 7, 231.	0.3	15
124	Update on Cryoablation for Treatment of Small Renal Mass: Oncologic Control, Renal Function Preservation, and Rate of Complications. Current Urology Reports, 2014, 15, 396.	1.0	15
125	Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology, 2016, 8, 257-271.	0.9	15
126	A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.	0.3	15



#	ARTICLE	IF	CITATIONS
127	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2022, 8, 182-190.	1.6	15
128	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 608-608.	0.8	15
129	Task-specific bench model training versus basic laparoscopic skills training for laparoscopic radical prostatectomy: a randomized controlled study. <i>Canadian Urological Association Journal</i> , 2013, 3, 22.	0.3	14
130	Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 3, 200.	0.3	14
131	A Prospective Randomized Study of Pfannenstiel Versus Expanded Port Site Incision for Intact Specimen Extraction in Laparoscopic Radical Nephrectomy. <i>Journal of Endourology</i> , 2015, 29, 913-918.	1.1	14
132	Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. <i>Canadian Urological Association Journal</i> , 2017, 11, 138.	0.3	14
133	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 12, 231-238.	0.3	14
134	Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis. <i>Genes</i> , 2020, 11, 874.	1.0	14
135	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019, 55, 1194-1212.	1.4	14
136	Inhibition of mtor in Kidney Cancer. <i>Current Oncology</i> , 2009, 16, 33-39.	0.9	13
137	Outcome of Third Renal Allograft Retransplants Versus Primary Transplants from Paired Donors. <i>Transplantation</i> , 2009, 87, 1214-1220.	0.5	13
138	Treatment of adult rhabdoid renal cell carcinoma with sorafenib. <i>Canadian Urological Association Journal</i> , 2013, 2, 631.	0.3	13
139	Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. <i>Canadian Urological Association Journal</i> , 2018, 13, 15-23.	0.3	13
140	Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. <i>Prostate</i> , 2018, 78, 953-961.	1.2	13
141	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 54, 112-118.	0.8	13
142	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, E325-30.	0.3	13
143	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.3	13
144	Prostate cancer screening: Attitudes and practices of family physicians in Ontario. <i>Canadian Urological Association Journal</i> , 2012, 6, 188-193.	0.3	12

#	ARTICLE	IF	CITATIONS
145	Laparoscopic nephrectomy for massive polycystic kidney disease: Updated technique and outcomes. Canadian Urological Association Journal, 2014, 8, 341.	0.3	12
146	CYB5D2 displays tumor suppression activities towards cervical cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 556-565.	1.8	12
147	Current management of metastatic renal cell carcinoma: evolving new therapies. Current Opinion in Supportive and Palliative Care, 2017, 11, 231-237.	0.5	12
148	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. Journal of Endourology, 2017, 31, 645-650.	1.1	12
149	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. Journal of Endourology, 2019, 33, 606-613.	1.1	12
150	<p>Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome</p>. Cancer Management and Research, 2019, Volume 11, 9307-9319.	0.9	12
151	The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert. Genes, 2020, 11, 312.	1.0	12
152	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. Clinical Genitourinary Cancer, 2020, 18, 314-321.e1.	0.9	11
153	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. Journal of Urology, 2021, 205, 78-85.	0.2	11
154	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.3	11
155	Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer – Results from a Prospective Cohort Study. Clinical Oncology, 2021, 33, 468-475.	0.6	11
156	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	0.8	11
157	TERMINAL LOOP CUTANEOUS URETEROSTOMY IN RENAL TRANSPLANTATION: AN UNDER UTILIZED URINARY DIVERSION TECHNIQUE. Journal of Urology, 2005, 174, 1906-1909.	0.2	10
158	Renal histopathology features according to various warm ischemia times in porcine laparoscopic and open surgery model. Canadian Urological Association Journal, 2011, 5, 40-43.	0.3	10
159	Laparoscopic partial nephrectomy: a challenging operation with a steep learning curve. Canadian Urological Association Journal, 2013, 3, 119.	0.3	10
160	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC – A Possible Path Forward. Kidney Cancer, 2017, 1, 31-40.	0.2	10
161	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 13, 166-174.	0.3	10
162	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. Canadian Urological Association Journal, 2018, 12, 243-251.	0.3	10

#	ARTICLE	IF	CITATIONS
163	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	1.2	10
164	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.3	10
165	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e610-e618.	0.9	10
166	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.3	10
167	Canadian Urological Association guideline: Management of small renal masses – Full-text. <i>Canadian Urological Association Journal</i> , 2021, 16, E61-75.	0.3	10
168	First-line treatment options in metastatic renal cell cancer. <i>Canadian Urological Association Journal</i> , 2016, 10, 236.	0.3	9
169	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. <i>Journal of Urology</i> , 2018, 200, 335-343.	0.2	9
170	Is There a Role for Adjuvant Therapy After Surgery in “High Risk for Recurrence” Kidney Cancer? an Update on Current Concepts. <i>Current Oncology</i> , 2018, 25, 444-453.	0.9	9
171	Circulating microvesicle protein is associated with renal transplant outcome. <i>Transplant Immunology</i> , 2019, 55, 101210.	0.6	9
172	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	0.9	9
173	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 836.e19-836.e27.	0.8	9
174	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2015, 9, 397.	0.3	8
175	Surgical Management of Stage T1 Renal Tumors in Canadian Academic Centers. <i>Canadian Urological Association Journal</i> , 2015, 9, 99.	0.3	8
176	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017, 11, 232-7.	0.3	8
177	Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice. <i>Canadian Urological Association Journal</i> , 2017, 12, E53-8.	0.3	8
178	Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. <i>Clinical Drug Investigation</i> , 2018, 38, 1155-1165.	1.1	8
179	The true malignancy risk of Bosniak III cystic renal lesions: Active surveillance or surgical resection?. <i>Canadian Urological Association Journal</i> , 2018, 12, E276-80.	0.3	8
180	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , 2018, 32, 621-629.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3471.	1.7	8
182	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	0.9	8
183	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , 2021, 38, 101588.	0.8	8
184	Renal cell carcinoma in renal allograft: Case series and review of literature. <i>Urology Annals</i> , 2018, 10, 229.	0.3	8
185	Commercial renal transplantation: A risky venture? A single Canadian centre experience. <i>Canadian Urological Association Journal</i> , 2011, 5, 335-340.	0.3	8
186	Review of the efficacy and safety of cryoablation for the treatment of small renal masses. <i>Canadian Urological Association Journal</i> , 2013, 7, E38-44.	0.3	8
187	Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 238.	0.3	7
188	Laparoscopic pyeloplasty: the updated McMaster University experience. <i>Canadian Urological Association Journal</i> , 2013, 2, 388.	0.3	7
189	Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. <i>Canadian Urological Association Journal</i> , 2017, 11, 222.	0.3	7
190	18F-DCFPyL PET/CT in Oncocytoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 921-924.	0.7	7
191	Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?. <i>Translational Oncology</i> , 2020, 13, 241-244.	1.7	7
192	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. <i>European Urology Focus</i> , 2021, 7, 818-826.	1.6	7
193	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. <i>Advances in Radiation Oncology</i> , 2021, 6, 100553.	0.6	7
194	Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network. <i>Cancers</i> , 2021, 13, 430.	1.7	7
195	Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. <i>PLoS ONE</i> , 2021, 16, e0253876.	1.1	7
196	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4596-TPS4596.	0.8	7
197	Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies. <i>Journal of Pathology Informatics</i> , 2017, 8, 43.	0.8	7
198	IQGAP2 Displays Tumor Suppression Functions. <i>Journal of Analytical Oncology</i> , 2015, 4, 86-93.	0.1	7

#	ARTICLE	IF	CITATIONS
199	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012, 6, 455-62.	0.3	7
200	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 41-47.	0.9	7
201	Current systemic management of metastatic renal cell carcinoma – first line and second line therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2011, 5, 211-221.	0.5	6
202	Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013, 7, 306.	0.3	6
203	Angiosarcoma of the adrenal gland with concurrent contralateral advanced renal cell carcinoma: A diagnostic and management dilemma. <i>Canadian Urological Association Journal</i> , 2015, 9, 302.	0.3	6
204	Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. <i>Data in Brief</i> , 2016, 6, 811-816.	0.5	6
205	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320.	0.3	6
206	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 377-383.	0.3	6
207	Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e9-798.e16.	0.8	6
208	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4516-4516.	0.8	6
209	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1340-1347.	2.3	6
210	Insights of RKIP-Derived Suppression of Prostate Cancer. <i>Cancers</i> , 2021, 13, 6388.	1.7	6
211	Identification of a novel Wee1 isoform. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1729, 1-9.	2.4	5
212	Specific Reduction of Fas-Associated Protein with Death Domain (FADD) in Clear Cell Renal Cell Carcinoma. <i>Cancer Investigation</i> , 2009, 27, 836-843.	0.6	5
213	Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. <i>Canadian Urological Association Journal</i> , 2013, 2, 175.	0.3	5
214	Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial. <i>Canadian Urological Association Journal</i> , 2020, 15, E97-E102.	0.3	5
215	Management of complex renal cysts in Canada: results of a survey study. <i>BMC Urology</i> , 2020, 20, 47.	0.6	5
216	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e1-239.e7.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021, 205, 1303-1309.	0.2	5
218	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4596-TPS4596.	0.8	5
219	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. <i>European Urology Focus</i> , 2022, 8, 1703-1710.	1.6	5
220	Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 157-165.	0.5	4
221	Kidney cancer, ESMO 2016. <i>Canadian Urological Association Journal</i> , 2016, 10, 227.	0.3	4
222	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e025662.	0.8	4
223	Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. <i>Clinical Oncology</i> , 2020, 32, e10-e15.	0.6	4
224	Immunohistochemistry Use by Diagnostic Category and Pathologist in 4477 Prostate Core Biopsy Sets Assessed at Two Hospitals. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 259-266.	0.6	4
225	Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 1569-1575.	1.2	4
226	Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 371.e17-371.e25.	0.8	4
227	Prognostic and Therapeutic Potential of the OIP5 Network in Papillary Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 4483.	1.7	4
228	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 962-970.	1.0	4
229	509: The Natural History of Small Renal Masses: A Prospective Multi-Center Canadian Trial. <i>Journal of Urology</i> , 2007, 177, 169-170.	0.2	4
230	Differences between the real and the desired worlds in the results of clinical trials. <i>Clinics</i> , 2015, 70, 618-622.	0.6	4
231	Canadian Urological Association Best Practice Report: Diagnosis and management of sporadic angiomyolipomas. <i>Canadian Urological Association Journal</i> , 2020, 14, E527-E536.	0.3	4
232	Pathologist workload, work distribution and significant absences or departures at a regional hospital laboratory. <i>PLoS ONE</i> , 2022, 17, e0265905.	1.1	4
233	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 210-218.	0.9	4
234	Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels. <i>Cancers</i> , 2022, 14, 2805.	1.7	4



#	ARTICLE	IF	CITATIONS
235	Laparoscopic partial nephrectomy: The McMaster University experience. Canadian Urological Association Journal, 2012, 6, 233-237.	0.3	3
236	L'invasion robotique au Canada. Canadian Urological Association Journal, 2014, 8, 466.	0.3	3
237	The robotic invasion in Canada. Canadian Urological Association Journal, 2014, 8, 151.	0.3	3
238	Renal tumour scoring systems: How useful are they?. Canadian Urological Association Journal, 2015, 9, 46.	0.3	3
239	Localized prostate cancer. Canadian Urological Association Journal, 2016, 10, 138.	0.3	3
240	Chemotherapy research for metastatic prostate cancer. Canadian Urological Association Journal, 2016, 10, 140.	0.3	3
241	Renal Cell Carcinoma in the Canadian Indigenous Population. Current Oncology, 2019, 26, 367-371.	0.9	3
242	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e11-576.e16.	0.8	3
243	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2019, 14, 122-129.	0.3	3
244	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. Canadian Urological Association Journal, 2019, 13, E377-E381.	0.3	3
245	A prospective, randomized, pilot trial of a polyethylene glycol (PEG)-coated collagen patch (Hemopatch <sup>®</sup> ) for intraoperative hemostasis during deceased donor renal transplant. Canadian Urological Association Journal, 2019, 14, E1-E5.	0.3	3
246	Development, implementation, and evaluation of a competency-based didactic and simulation-focused boot camp for incoming urology residents: Report of the first three years. Canadian Urological Association Journal, 2020, 15, 98-105.	0.3	3
247	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal, 2020, 15, E90-E96.	0.3	3
248	Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes. Canadian Urological Association Journal, 2020, 14, 337-345.	0.3	3
249	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer, 2021, 5, 21-29.	0.2	3
250	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology, 2015, 33, 4555-4555.	0.8	3
251	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology, 2017, 35, 4514-4514.	0.8	3
252	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	0.8	3



#	ARTICLE	IF	CITATIONS
253	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2019, 37, 568-568.	0.8	3
254	Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. Canadian Urological Association Journal, 2020, 14, E527-E536.	0.3	3
255	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). Clinical Genitourinary Cancer, 2022, 20, e353-e361.	0.9	3
256	A Platform of High-Efficiency Nonviral Gene Transfer in Mouse Osteoblast Cells In Vitro. Molecular Biotechnology, 2006, 34, 29-36.	1.3	2
257	Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. Current Oncology, 2009, 16, .	0.9	2
258	Laparoscopic right donor nephrectomy. BJU International, 2009, 103, 998-1013.	1.3	2
259	Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma. Current Urology, 2009, 2, 188-193.	0.4	2
260	A System for Laparoscopic Surgery Ergonomics and Skills Evaluation. Journal of Endourology, 2011, 25, 1111-1114.	1.1	2
261	Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2013, 64, 518-519.	0.9	2
262	â€œI told you soâ€: Examining the impact of the surgical safety checklist. Canadian Urological Association Journal, 2014, 8, 79.	0.3	2
263	Whatâ€™s new in prostate cancer research? Highlights of GU-ASCO 2014. Canadian Urological Association Journal, 2014, 8, 8.	0.3	2
264	PSA screening: And nowâ€¦ a message from our experts. Canadian Urological Association Journal, 2014, 8, 387.	0.3	2
265	Renal cell carcinoma and amyopathic dermatomyositis. Canadian Urological Association Journal, 2015, 9, 340.	0.3	2
266	Whatâ€™s New in Prostate Cancer Research? Highlights of GU-ASCO 2015. Canadian Urological Association Journal, 2015, 9, 148.	0.3	2
267	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. Canadian Urological Association Journal, 2018, 12, E415-20.	0.3	2
268	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. Canadian Urological Association Journal, 2019, 14, 24-30.	0.3	2
269	Expert and Crowdsourced Evaluation of Image Quality From a Novel Endoscopy Phone Light Adapter. Urology, 2020, 146, 54-58.	0.5	2
270	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. Canadian Urological Association Journal, 2020, 14, E387-E393.	0.3	2

#	ARTICLE	IF	CITATIONS
271	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 271-280.	0.8	2
272	Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel towards Prostate Cancer Relapse. Genes, 2021, 12, 257.	1.0	2
273	Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management. Canadian Urological Association Journal, 2021, 15, 413-419.	0.3	2
274	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.	0.3	2
275	The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 499.e15-499.e22.	0.8	2
276	Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.. Journal of Clinical Oncology, 2014, 32, 420-420.	0.8	2
277	Emphysematous pyelonephritis in failed renal allograft: Case report and review of literature. Urology Annals, 2016, 8, 111.	0.3	2
278	Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. Current Oncology, 2021, 28, 226-232.	0.9	2
279	McMaster experience with laparoscopic pyeloplasty. Canadian Journal of Urology, 2004, 11, 2299-302.	0.0	2
280	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. Urology, 2022, , .	0.5	2
281	Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncologica, 2022, 61, 705-713.	0.8	2
282	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. Journal of Urology, 2022, 208, 804-812.	0.2	2
283	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). Drug, Healthcare and Patient Safety, 2010, 2, 85.	1.0	1
284	1340 DESIGNING A HIGH-FIDELITY LAPAROSCOPIC PARTIAL NEPHRECTOMY MODEL: DETERMINING THE TISSUE RESISTANCE AND TEAR STRENGTH OF THE RENAL CAPSULE. Journal of Urology, 2010, 183, .	0.2	1
285	Comparison of laparoscopic donor nephrectomy with open donor nephrectomy: McMaster University experience and operative technique. Indian Journal of Transplantation, 2011, 5, 191-194.	0.0	1
286	1491 DESIGNING A HIGH-FIDELITY LAPAROSCOPIC PARTIAL NEPHRECTOMY BENCH MODEL: DETERMINING THE TEAR STRENGTH AND RESISTANCE OF A SYNTHETIC SILICONE COMPOSITION. Journal of Urology, 2011, 185, .	0.2	1
287	Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines. Canadian Urological Association Journal, 2012, 1, S34-40.	0.3	1
288	« Je vous lâ€™avais bien dit Â» : Examen de lâ€™incidence de la liste de contrÃ¢le de la sÃ©curitÃ© chirurgicale. Canadian Urological Association Journal, 2014, 8, 221.	0.3	1

#	ARTICLE	IF	CITATIONS
289	New paradigms in the treatment of genitourinary malignancies: GU-ASCO Update 2014. Canadian Urological Association Journal, 2014, 8, 7.	0.3	1
290	MP64-06 RECURRENCE AND SURVIVAL AFTER PARTIAL VERSUS RADICAL NEPHRECTOMY FOR T1 RENAL MASS. Journal of Urology, 2014, 191, .	0.2	1
291	What's New in Renal Cell Cancer Research? Highlights of GU-ASCO 2015. Canadian Urological Association Journal, 2015, 9, 154.	0.3	1
292	Radionuclides. Canadian Urological Association Journal, 2016, 10, 144.	0.3	1
293	Androgen receptor axis-targeted agents. Canadian Urological Association Journal, 2016, 10, 146.	0.3	1
294	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open, 2017, 5, E834-E841.	1.1	1
295	Evolution of the CUA guideline "Raising the bar!". Canadian Urological Association Journal, 2018, 12, 151.	0.3	1
296	The role and timing of cytoreductive nephrectomy in the immunotherapy era. European Urology Focus, 2020, 6, 7-8.	1.6	1
297	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association Journal, 2020, 15, 132-137.	0.3	1
298	Surveillance post-radiofrequency ablation for small renal masses: Recurrence and followup. Canadian Urological Association Journal, 2020, 14, 398-403.	0.3	1
299	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4cm renal cell carcinomas. Cancer Causes and Control, 2021, 32, 119-126.	0.8	1
300	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2021, 39, 4554-4554.	0.8	1
301	MUCIN 1 in Prostate Cancer. , 0, , 125-138.		1
302	Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 2021, , .	0.5	1
303	The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. Canadian Urological Association Journal, 2021, 16, .	0.3	1
304	Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib"Single center experience. Journal of Clinical Oncology, 2008, 26, 16141-16141.	0.8	1
305	The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. Journal of Clinical Oncology, 2015, 33, 424-424.	0.8	1
306	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	0.8	1

#	ARTICLE	IF	CITATIONS
307	Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.. Journal of Clinical Oncology, 2014, 32, 434-434.	0.8	1
308	The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.. Journal of Clinical Oncology, 2015, 33, 480-480.	0.8	1
309	Acute care for renal colic in Canadian healthcare â€” a commentary on emergency department patient flow metrics and treatment options. Canadian Urological Association Journal, 2020, 14, 265-266.	0.3	1
310	Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology, 2020, 22, 437.	0.8	1
311	Downregulation of the Raf kinase inhibitory protein (RKIP) in clear cell renal cell carcinoma associates with poor prognosis. , 2020, , 435-457.		1
312	Canadian Urological Association guideline: Management of small renal masses â€” Summary of recommendations. Canadian Urological Association Journal, 2021, 16, 24-5.	0.3	1
313	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology, 2022, 7, 100899.	0.6	1
314	Management of adult tuberous sclerosis complex-related angiomyolipoma: A single-center experience. Canadian Urological Association Journal, 2021, 16, .	0.3	1
315	1289: Lower Plasma Adiponectin Levels as a Potential Biomarker for Renal Cell Carcinoma. Journal of Urology, 2007, 177, 424-425.	0.2	0
316	TRANSFER OF LAPAROSCOPIC RADICAL PROSTATECTOMY SKILLS FROM BENCH MODEL TO ANIMAL MODEL: A RANDOMIZED CONTROL STUDY. Journal of Urology, 2008, 179, 659-659.	0.2	0
317	LIVING UNRELATED (COMMERCIAL) RENAL TRANSPLANTATION: A SINGLE CANADIAN CENTRE EXPERIENCE. Journal of Urology, 2008, 179, 664-664.	0.2	0
318	Spontaneous regression of an untreated lung cancer. Indian Journal of Thoracic and Cardiovascular Surgery, 2010, 26, 173-175.	0.2	0
319	388 COST-UTILITY OF RADICAL NEPHRECTOMY VERSUS PARTIAL NEPHRECTOMY IN THE MANAGEMENT OF SMALL RENAL MASSES: ADJUSTING FOR THE BURDEN OF CHRONIC RENAL FAILURE. Journal of Urology, 2011, 185, .	0.2	0
320	168 DEFINING CONDITIONS TO GENERATE AND MAINTAIN PROSTATE CANCER STEM CELLS. Journal of Urology, 2011, 185, .	0.2	0
321	233 ACTIVATION OF ADIPONECTIN RECEPTOR 1 (ADIPOR1) WHICH IS UNDER-EXPRESSED IN KIDNEY CANCER INDUCES TUMOR SUPPRESSION. Journal of Urology, 2011, 185, .	0.2	0
322	396 PRESENCE OF GRP78 ON THE CELL SURFACE OF KIDNEY CANCER CELLS CORRELATES WITH INCREASED ANTI-GRP78 AUTOANTIBODY TITRES IN KIDNEY CANCER PATIENTS- A POTENTIAL NOVEL DIAGNOSTIC MARKER. Journal of Urology, 2011, 185, .	0.2	0
323	641 MANAGEMENT OF THE INTRAVESICAL URETER AND BLADDER CUFF DURING RADICAL NEPHROURETERECTOMY: OUTCOMES FROM THE CANADIAN UPPER TRACT COLLABORATION. Journal of Urology, 2012, 187, .	0.2	0
324	1920 PROSTATE CANCER SCREENING ATTITUDES AND PRACTICES OF FAMILY PHYSICIANS IN ONTARIO. Journal of Urology, 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
325	Uncertainty in ultrasound reporting. Canadian Urological Association Journal, 2012, 1, 255.	0.3	0
326	Canadian content at GU-ASCO 2014: Highlights of research involving Canadian researchers. Canadian Urological Association Journal, 2014, 8, 16.	0.3	0
327	What's new in renal cell cancer research? Highlights of GU-ASCO 2014. Canadian Urological Association Journal, 2014, 8, 13.	0.3	0
328	MP57-18 SHORT-TERM OUTCOME OF METASTASECTOMY IN RENAL CELL CARCINOMA: THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM INITIAL EXPERIENCE.. Journal of Urology, 2014, 191, .	0.2	0
329	MP40-02 INCREASED UPTAKE OF RENAL TUMOUR BIOPSIES FOR SMALL RENAL MASSES – RESULTS OF A MULTICENTRE CANADIAN EXPERIENCE. Journal of Urology, 2014, 191, .	0.2	0
330	PD17-11 POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: PREDICTORS AND IMPACT ON ONCOLOGICAL OUTCOMES. Journal of Urology, 2014, 191, .	0.2	0
331	PD10-12 CLINICAL OUTCOMES FOLLOWING LAPAROSCOPIC MANAGEMENT OF PT3 RENAL MASSES: A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
332	MP59-16 RENAL ARTERY PSEUDOANEURYSMS AFTER NEPHRON SPARING SURGERY FOR RENAL CELL CARCINOMA: INCIDENCE, MANAGEMENT AND FUNCTIONAL OUTCOMES FROM CANADIAN KIDNEY CANCER INFORMATION SYSTEM DATABASE.. Journal of Urology, 2014, 191, .	0.2	0
333	PD25-10 RESIDENT INVOLVEMENT IN ENDOSCOPIC BLADDER CANCER SURGERY IS ASSOCIATED WITH INADEQUATE PATHOLOGY SPECIMENS AND PROLONGED TIME TO CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	0
334	MP57-20 VARIANT HISTOLOGY DOES NOT PREDICT SURVIVAL OUTCOMES AFTER RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE CANADIAN UPPER TRACT COLLABORATION. Journal of Urology, 2015, 193, .	0.2	0
335	MP84-08 PATHOLOGICAL UPSTAGING OF CLINICAL T1 RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES. Journal of Urology, 2015, 193, .	0.2	0
336	Current Concepts in Genitourinary Oncology: GU-ASCO 2015. Canadian Urological Association Journal, 2015, 9, 147.	0.3	0
337	MP50-19 CONTRAST-ENHANCED ULTRASOUND FOR SURVEILLANCE OF RADIOFREQUENCY-ABLATED RENAL TUMORS: RESULTS FROM A PROSPECTIVE PILOT STUDY. Journal of Urology, 2015, 193, .	0.2	0
338	Prostate cancer update from the American Society of Clinical Oncology (ASCO) annual meeting 2016. Canadian Urological Association Journal, 2016, 10, 137.	0.3	0
339	Update from the European Association of Urology (EAU) Annual Meeting 2016. Canadian Urological Association Journal, 2016, 10, 123.	0.3	0
340	What's new in testosterone deficiency research?. Canadian Urological Association Journal, 2016, 10, 130.	0.3	0
341	Sunitinib: 10 years of clinical experience in the treatment of advanced renal cell carcinoma. Canadian Urological Association Journal, 2016, 10, 235.	0.3	0
342	Update on Bladder, Kidney, and Prostate Cancer from the European Society for Medical Oncology (ESMO) Annual Meeting 2016. Canadian Urological Association Journal, 2016, 10, 223.	0.3	0

#	ARTICLE	IF	CITATIONS
343	Intrinsic ureteral endometriosis as a cause of unilateral obstructive uropathy. Canadian Urological Association Journal, 2016, 10, 119.	0.3	0
344	What's new renal cancer research?. Canadian Urological Association Journal, 2016, 10, 132.	0.3	0
345	What's new in prostate cancer research?. Canadian Urological Association Journal, 2016, 10, 127.	0.3	0
346	MP75-09 THE NATURAL HISTORY OF RENAL FUNCTION AFTER SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM. Journal of Urology, 2016, 195, .	0.2	0
347	PD37-01 FOUR VS TEN MONTHS OF INDUCTION ADT FOR INTERMITTENT THERAPY: A PROSPECTIVE CURC RANDOMIZED TRIAL.. Journal of Urology, 2017, 197, .	0.2	0
348	Reply by the Authors. Urology, 2017, 100, 255.	0.5	0
349	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data. Annals of Oncology, 2017, 28, v319.	0.6	0
350	Highlights of genitourinary cancer research presented at ASCO 2017. Canadian Urological Association Journal, 2017, 11, S297.	0.3	0
351	New research in bladder cancer, ASCO 2017. Canadian Urological Association Journal, 2017, 11, S301-2.	0.3	0
352	New research in prostate cancer, ASCO 2017. Canadian Urological Association Journal, 2017, 11, S303-4.	0.3	0
353	Update from the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium (ASCO-GU). Canadian Urological Association Journal, 2017, 11, 159.	0.3	0
354	New research in kidney cancer, ASCO 2017. Canadian Urological Association Journal, 2017, 11, S298-300.	0.3	0
355	Effect of African-American race on cancer specific mortality differs according to clear-cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. European Urology Supplements, 2018, 17, e72-e75.	0.1	0
356	Is nephrectomy no longer beneficial in the management of metastatic kidney cancer?. Canadian Urological Association Journal, 2018, 13, 151.	0.3	0
357	Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer. Canadian Urological Association Journal, 2019, 13, 404-405.	0.3	0
358	Cost-Effectiveness of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) in the Treatment of Localized Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, e393-e394.	0.4	0
359	Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics, 2020, 108, e887.	0.4	0
360	Images " Rare diagnosis of high-grade, undifferentiated pelvic sarcoma for urinary dysfunction in a young man. Canadian Urological Association Journal, 2020, 15, E192-E194.	0.3	0



#	ARTICLE	IF	CITATIONS
361	Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression. <i>Advances in Stem Cells and Their Niches</i> , 2021, 5, 177-204.	0.1	0
362	Reply By Authors. <i>Journal of Urology</i> , 2021, 205, 84-85.	0.2	0
363	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. <i>Société Internationale D'urologie Journal</i> , 2021, 2, 82-95.	0.2	0
364	PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5064-5064.	0.8	0
365	Development and initial validation of a cost-effective, re-usable, ultrasound-compatible suprapubic catheter insertion training simulator. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	0
366	Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear cell carcinoma of the kidney. <i>Journal of Clinical Oncology</i> , 2008, 26, 22225-22225.	0.8	0
367	Correlation of computerized tomography measurement of visceral adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5118-5118.	0.8	0
368	Preferred management option for small renal masses: laparoscopic partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2010, 4, 139-141.	0.3	0
369	Improving outcomes through the development of quality indicators in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 422-422.	0.8	0
370	TRANSPLANTATION OF PEDIATRIC ENBLOC CADAVER KIDNEYS INTO ADULT RECIPIENTS. <i>Transplantation</i> , 1998, 65, S108.	0.5	0
371	Oncology Brief from ASCO 2015: Update on Kidney Cancer and Prostate Cancer. <i>Canadian Urological Association Journal</i> , 2015, 9, 157.	0.3	0
372	Nucleic acid amplification techniques (NAATs) for early diagnosis of HIV-1 and HIV-2 infections. <i>The Cochrane Library</i> , 0, , .	1.5	0
373	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16078-e16078.	0.8	0
374	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16065-e16065.	0.8	0
375	Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4580-4580.	0.8	0
376	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 621-621.	0.8	0
377	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4597-TPS4597.	0.8	0
378	A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.. <i>Journal of Clinical Oncology</i> , 2019, 37, 161-161.	0.8	0



#	ARTICLE	IF	CITATIONS
379	Reply by Authors. Journal of Urology, 2019, 202, 1274-1274.	0.2	0
380	Introduction of Mini-clinical Evaluation Exercise for the Formative Assessment of Postgraduates in the General Surgery Discipline. Journal of Clinical and Diagnostic Research JCDR, 0, , .	0.8	0
381	Practice-changing publications: Kidney cancer. Canadian Urological Association Journal, 2021, 16, E237-9.	0.3	0